Talent
Investor Portal
About
What We Do
FAQs
Sectors
Deep Tech
Life Sciences
Health Tech
Portfolio
Team
News
Contact
Newsroom
latest news from ose
and across our portfolio
Featured News
August 31, 2023
Oxford Science Enterprises Appoints Ed Bussey as Chief Executive Officer
Article links to www.beacontx.com
June 12, 2023
Beacon Therapeutics launches with £96 million to develop a new generation of gene therapies for retinal diseases
Article links to www.caristo.com
April 17, 2023
Caristo Diagnostics Completes Series A Financing and Welcomes New CEO
Article links to quantummotion.tech
February 21, 2023
Quantum Motion Raises £42 Million Investment Round
Article links to spybiotech.com
March 20, 2023
SpyBiotech Receives Grant from the Bill & Melinda Gates Foundation
February 7, 2023
Our 2022 Highlights
Article links to innovation.ox.ac.uk
May 22, 2023
Oxford University retains No. 1 spot for spinouts
Article links to www.ultromics.com
April 26, 2023
Ultromics granted FDA Breakthrough Device Designation
All News
21•06•23
Portfolio News
Vaccitech
Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B
17•04•23
Portfolio News
Vaccitech
Vaccitech’s VTP-200 Ph 1b/2 Study Demonstrates Favorable Tolerability and Immunogenicity Profile in Women with HPV
31•01•23
Portfolio News
Vaccitech
Vaccitech appoints industry veteran, Nadège Pelletier, Ph.D., as Chief Scientific Officer
21•11•22
Portfolio News
Vaccitech
Vaccitech to host KOL webinar on the SNAPvax™ platform for inducing tolerance to treat celiac and other autoimmune diseases
10•11•22
Portfolio News
Vaccitech
Vaccitech reports third quarter 2022 financial results and recent corporate developments
08•08•22
Portfolio News
Vaccitech
Vaccitech reports second quarter 2022 financial results and recent corporate developments
21•06•22
Portfolio News
Vaccitech
Vaccitech’s VTP-300 induced sustained reductions of surface antigen in patients with chronic hepatitis B both as a monotherapy and in combination with a single low dose of anti-PD-1
05•06•22
Portfolio News
Vaccitech
Arbutus and Vaccitech dose first patient in Phase 2a clinical trial combining therapies for the treatment of chronic hepatitis B virus
06•04•22
Portfolio News
Vaccitech
Vaccitech announces notification of milestone and royalty revenue relating to sales of Vaxzevria
25•03•22
Portfolio News
Vaccitech
Vaccitech reports full-year 2021 financial results and recent corporate developments
18•01•22
Portfolio News
Vaccitech
Vaccitech announces Cancer Research UK dose first patient in Phase I/IIa trial of lung cancer immunotherapy vaccine
13•12•21
Portfolio News
Vaccitech
Vaccitech acquires Avidea Technologies to expand product pipeline and strengthen scientific leadership in immunotherapies and vaccines
07•12•21
Portfolio News
Vaccitech
Vaccitech reports promising interim efficacy analysis in Phase 1b/2a clinical study in chronic HBV
12•11•21
Portfolio News
Vaccitech
Vaccitech reports third quarter 2021 financial results and recent corporate developments
12•11•21
Portfolio News
Vaccitech
Vaccitech’s VTP-300 was well-tolerated and induced T cells against all targeted HBV antigens in both healthy volunteers and patients with chronic HBV infection in interim analyses
04•11•21
Portfolio News
Vaccitech
Vaccitech announces publication of second Phase 1 clinical trial results of ChAdOx1 vaccine in development for the MERS coronavirus
06•07•21
Portfolio News
Vaccitech
Arbutus Biopharma and Vaccitech announce clinical trial collaboration for chronic hepatitis B virus infection
03•05•21
Portfolio News
Vaccitech
Vaccitech announces closing of $110.5 million initial public offering
28•04•21
Portfolio News
Vaccitech
Vaccitech announces pricing of initial public offering
22•03•21
Portfolio News
Vaccitech
Vaccitech appoints Joseph Scheeren, PharmD, to its Board of Directors
18•03•21
Portfolio News
Vaccitech
Vaccitech doses first patient in HPV001, a Phase 1/2 clinical trial of VTP-200 immunotherapeutic for high-risk persistent HPV infection
17•03•21
Portfolio News
Vaccitech
Vaccitech completes $168 million Series B financing to advance three clinical programs through Phase 2 results
02•03•21
Portfolio News
Vaccitech
Vaccitech appoints two independent board directors
01•02•21
Portfolio News
Vaccitech
Vaccitech doses first patient in HBV002, a Phase 1b/2a clinical trial of VTP-300 immunotherapeutic candidate for chronic HBV patients
23•11•20
OSE News
Vaccitech
Breakthrough for Oxford's covid vaccine, co-invented by Vaccitech
19•10•20
Portfolio News
Vaccitech
Vaccitech expands management team with new hires, including CMO and CFO
29•04•20
Portfolio News
Vaccitech
Vaccitech and Oxford University announce landmark partnership with AstraZeneca for the development and large-scale distribution of the COVID-19 vaccine candidate
Menu
About
What We Do
FAQs
Sectors
Deep Tech
Life Sciences
Health Tech
Portfolio
Team
News
Contact
Talent
Investor Portal